Mesoblast Ltd
ASX:MSB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.26
1.78
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Mesoblast Ltd
Mesoblast Ltd
PP&E Net
Mesoblast Ltd
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mesoblast Ltd
ASX:MSB
|
PP&E Net
$3.8m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Immutep Ltd
ASX:IMM
|
PP&E Net
AU$679.7k
|
CAGR 3-Years
30%
|
CAGR 5-Years
67%
|
CAGR 10-Years
2%
|
|
|
CSL Ltd
ASX:CSL
|
PP&E Net
$9.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
17%
|
CAGR 10-Years
18%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
PP&E Net
AU$7.7m
|
CAGR 3-Years
44%
|
CAGR 5-Years
61%
|
CAGR 10-Years
53%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
PP&E Net
AU$30.5m
|
CAGR 3-Years
85%
|
CAGR 5-Years
167%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
PP&E Net
AU$1.6m
|
CAGR 3-Years
2%
|
CAGR 5-Years
27%
|
CAGR 10-Years
17%
|
|
Mesoblast Ltd
Glance View
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 83 full-time employees. The company went IPO on 2004-12-16. The firm is using its mesenchymal lineage cell technology platform to develop and commercialize allogeneic cellular medicines to treat complex inflammatory diseases. Its product candidate includes Remestemcel-L ((RYONCIL) for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), Rexlemestrocel-L (REVASCOR) for the advanced chronic heart failure (CHF) and MPC-06-ID for the treatment of chronic low back pain caused by disc degeneration (CLBP). Its product candidate MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction. Its product candidate also includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy.
See Also
What is Mesoblast Ltd's PP&E Net?
PP&E Net
3.8m
USD
Based on the financial report for Jun 30, 2024, Mesoblast Ltd's PP&E Net amounts to 3.8m USD.
What is Mesoblast Ltd's PP&E Net growth rate?
PP&E Net CAGR 5Y
36%
Over the last year, the PP&E Net growth was -41%. The average annual PP&E Net growth rates for Mesoblast Ltd have been -32% over the past three years , 36% over the past five years .
You don't have any saved screeners yet
